Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark P. Smith, MD
Merck Serono Co., Ltd., Japan
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Aichi, Japan
- National Cancer Center East Hospital
Chiba, Japan
- Research Site
Ehime, Japan
- Research Site
Hokkaido, Japan
- Research Site
Kanagawa, Japan
- Tokai University
Kanagawa, Japan
- Research Site
Osaka, Japan
- Research Site
Shizuoka, Japan
- Research Site
Tochigi, Japan
- Research Site
Tokyo, Japan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2009
- Primary completion
- 31 Mar 2011
- Completion
- —
- Last update posted
- 8 Apr 2014
- Registered enrollment
- 33
- Registry id
- NCT00971932
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.